The drug aims to provide new evidence to help diagnose MS and evaluate the scope of damage inflicted on the central nervous system.
Researchers from Cleveland-based Case Western Reserve University developed the drug, which will be tested in healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.
Administered through an IV before a PET scan, Myeliviz targets and binds to myelin, the casing surrounding nerves affected by MS.
The National Institutes of Health provided a $1.7 million grant to make the trial possible.
More articles on biologics:
Dr. Fred Naraghi: Cervical disc replacement, spinal fusion will continue to be dominant procedures
$186M in Q4 sales delivered by Novartis gene therapy for spinal muscular atrophy
HSS opens 1st Florida hospital, 2nd new facility in 1 week
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
